Single-Cell Optical Action Potential Measurement in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
December 22nd, 2020
Here we describe optical acquisition and characterization of action potentials from induced pluripotent stem cell derived cardiomyocytes using a high-speed modular photometry system.
Overview
This protocol describes the optical acquisition and characterization of action potentials from induced pluripotent stem cell-derived cardiomyocytes using a high-speed modular photometry system. It offers a high throughput method for measuring cellular electrophysiology, simplifying traditional techniques.
Key Study Components
Area of Science
- Electrophysiology
- Stem Cell Biology
- Cardiomyocyte Function
Background
- Induced pluripotent stem cells can be differentiated into cardiomyocytes.
- Traditional patch clamp techniques are complex and labor-intensive.
- High-speed photometry provides a less complex alternative.
- This method can support large-scale toxicity screening programs.
Purpose of Study
- To develop a protocol for high throughput measurements of cardiomyocyte electrophysiology.
- To compare the effectiveness of photometry with traditional methods.
- To facilitate large-scale screening for drug toxicity.
Methods Used
- Coating glass cover slips with basement membrane matrix.
- Incubating cover slips at low temperatures.
- Applying cell cultures to prepared cover slips.
- Using a high-speed modular photometry system for measurements.
Main Results
- The protocol yields results comparable to traditional methods.
- It allows for efficient preparation and measurement of cardiomyocytes.
- Supports comprehensive in vitro proarrhythmia assays.
- Enables large-scale studies with human-derived cells.
Conclusions
- This method simplifies the process of measuring action potentials.
- It can be effectively used in toxicity screening programs.
- The protocol enhances the accessibility of cardiomyocyte research.
Frequently Asked Questions
Executive Industry Relevance
High-throughput, single-cell optical action potential measurement in human iPSC-derived cardiomyocytes addresses the need for scalable, predictive cardiac electrophysiology platforms in early drug discovery. This approach enables rapid, quantitative assessment of cardiotoxicity risk and functional target validation, supporting portfolio triage and de-risking at the preclinical stage. The method's compatibility with large-scale screening aligns with enterprise R&D priorities for efficient, human-relevant safety evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of cardiac ion channel activity in human-relevant systems.
- Supports mechanistic de-risking by quantifying action potential dynamics at single-cell resolution.
- Facilitates predictive confidence in target validation for cardiac safety liabilities.
Screening & Assay Development
- Prepares standardized, reproducible iPSC-cardiomyocyte assays for downstream compound screening.
- Delivers quantitative, high-throughput electrophysiological readouts suitable for proarrhythmia risk assessment.
- Enables scalable assay platforms for reliable evaluation of drug-induced cardiac effects.
Translational & Preclinical Research
- Aligns in vitro cardiac models with translational biomarker endpoints for preclinical safety studies.
- Provides continuity from early discovery through preclinical validation of cardiac risk.
- Supports risk-adjusted advancement decisions based on human cell-derived electrophysiological data.
Pipeline & Workflow Integration
This optical measurement platform integrates from early discovery through lead identification and preclinical safety workflows, enabling robust cardiac risk assessment in human iPSC-derived systems.
- Discovery Biology: Supports hypothesis testing and mechanistic clarification of cardiac electrophysiology.
- Screening: Provides reproducible, quantitative action potential measurements for compound triage.
- Analytics: Enables statistical comparison of action potential parameters across conditions and compounds.
- Translational Research: Bridges in vitro findings to preclinical safety endpoints using human-relevant models.
- Enterprise Reuse: Offers a modular, scalable platform adaptable to diverse cardiac safety and efficacy studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac safety assessment.
- Operational Value: Streamlines workflows with standardized, high-throughput, and less labor-intensive protocols.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enabling early detection of cardiac liabilities.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of drug candidates with improved safety profiles.
Implementation Considerations
- Requires expertise in iPSC culture, electrophysiology, and optical imaging.
- Needs modular photometry instrumentation and compatible data acquisition systems.
- Demands cross-team standardization of assay protocols and analysis pipelines.
- Adaptable to various iPSC-derived cardiac models and pharmacological manipulations.
- Excitation light exposure must be minimized to preserve cell viability during repeated measurements.
Biopharma FAQs
Chapters in this video
0:05
Introduction
0:45
Cell Preparation
1:35
Microscope Setup
3:28
Voltage Sensitive Dye Cell Loading
4:24
Electrical Field Stimulation
4:59
Optical Action Potential (AP) Acquisition
6:01
Data Analysis
6:55
Results: Representative Optical AP Profiles of Isolated Native Murine and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
7:59
Conclusion
